Geode Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,075,075
| Closed | -$83.5M | – | 4453 |
|
|
2026
Q1 | $83.5M | Buy |
2,075,075
+49,406
| +2% | +$1.06M | 0.01% | 1203 |
|
|
2025
Q4 | $50.9M | Sell |
2,025,669
-47,244
| -2% | -$1.11M | ﹤0.01% | 1470 |
|
|
2025
Q3 | $46.9M | Buy |
2,072,913
+77,642
| +4% | +$1.81M | ﹤0.01% | 1502 |
|
|
2025
Q2 | $34.5M | Buy |
1,995,271
+45,225
| +2% | +$837K | ﹤0.01% | 1632 |
|
|
2025
Q1 | $42.7M | Buy |
1,950,046
+111,094
| +6% | +$3.07M | ﹤0.01% | 1468 |
|
|
2024
Q4 | $58.7M | Buy |
1,838,952
+28,426
| +2% | +$855K | ﹤0.01% | 1331 |
|
|
2024
Q3 | $52.2M | Buy |
1,810,526
+22,609
| +1% | +$837K | ﹤0.01% | 1399 |
|
|
2024
Q2 | $68.6M | Buy |
1,787,917
+98,027
| +6% | +$4.44M | 0.01% | 1152 |
|
|
2024
Q1 | $99.4M | Buy |
1,689,890
+59,248
| +4% | +$3.78M | 0.01% | 923 |
|
|
2023
Q4 | $97.6M | Buy |
1,630,642
+75,816
| +5% | +$3.85M | 0.01% | 885 |
|
|
2023
Q3 | $59.2M | Buy |
1,554,826
+56,437
| +4% | +$2.48M | 0.01% | 1121 |
|
|
2023
Q2 | $137M | Sell |
1,498,389
-339,890
| -18% | -$29.3M | 0.02% | 636 |
|
|
2023
Q1 | $121M | Buy |
1,838,279
+88,278
| +5% | +$5.09M | 0.02% | 658 |
|
|
2022
Q4 | $90.5M | Buy |
1,750,001
+58,799
| +3% | +$3.12M | 0.01% | 763 |
|
|
2022
Q3 | $116M | Buy |
1,691,202
+81,040
| +5% | +$4.8M | 0.02% | 629 |
|
|
2022
Q2 | $72.8M | Buy |
1,610,162
+116,642
| +8% | +$5.32M | 0.01% | 868 |
|
|
2022
Q1 | $75.9M | Buy |
1,493,520
+140,691
| +10% | +$6.21M | 0.01% | 944 |
|
|
2021
Q4 | $64M | Buy |
1,352,829
+164,437
| +14% | +$6.47M | 0.01% | 1118 |
|
|
2021
Q3 | $39.2M | Buy |
1,188,392
+70,257
| +6% | +$3.95M | 0.01% | 1471 |
|
|
2021
Q2 | $70.7M | Buy |
1,118,135
+71,222
| +7% | +$3.68M | 0.01% | 1020 |
|
|
2021
Q1 | $44.9M | Buy |
1,046,913
+110,380
| +12% | +$5.22M | 0.01% | 1317 |
|
|
2020
Q4 | $53.6M | Buy |
936,533
+58,719
| +7% | +$2.48M | 0.01% | 1046 |
|
|
2020
Q3 | $26.5M | Buy |
877,814
+11,916
| +1% | +$356K | 0.01% | 1318 |
|
|
2020
Q2 | $28.3M | Buy |
865,898
+37,849
| +5% | +$1.22M | 0.01% | 1247 |
|
|
2020
Q1 | $22.2M | Buy |
828,049
+170,112
| +26% | +$6.04M | 0.01% | 1223 |
|
|
2019
Q4 | $20.1M | Buy |
657,937
+31,187
| +5% | +$863K | ﹤0.01% | 1553 |
|
|
2019
Q3 | $15.1M | Buy |
626,750
+48,753
| +8% | +$1.34M | ﹤0.01% | 1657 |
|
|
2019
Q2 | $14.6M | Buy |
577,997
+90,565
| +19% | +$1.84M | ﹤0.01% | 1691 |
|
|
2019
Q1 | $9.5M | Buy |
487,432
+65,583
| +16% | +$1.03M | ﹤0.01% | 1930 |
|
|
2018
Q4 | $5.56M | Buy |
421,849
+48,603
| +13% | +$746K | ﹤0.01% | 2156 |
|
|
2018
Q3 | $6.64M | Buy |
373,246
+13,044
| +4% | +$241K | ﹤0.01% | 2185 |
|
|
2018
Q2 | $7.92M | Buy |
360,202
+210,210
| +140% | +$4.83M | ﹤0.01% | 2053 |
|
|
2018
Q1 | $3.32M | Buy |
149,992
+3,797
| +3% | +$74.6K | ﹤0.01% | 2490 |
|
|
2017
Q4 | $3.17M | Buy |
+146,195
| New | +$2.15M | ﹤0.01% | 2486 |
|
Other funds holding APLS
Geode Capital Management's APLS Position: Q2 2026 in Review
Geode Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,075,075 shares — an estimated $83.5M sold.
Geode Capital Management first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $137M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Geode Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Geode Capital Management sold 2,075,075 Apellis Pharmaceuticals shares in Q2 2026, an estimated $83.5M.
- Geode Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Geode Capital Management's Apellis Pharmaceuticals position peaked at $137M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.